Biotech · Public company · Cambridge, MA, US

Immuneering Corp

Ticker IMRX · SEC CIK 0001790340

Track this companyFree. Adds Immuneering Corp to your Dealase workspace and tells you when its record changes.

Clinical trials32 recruiting or active

Pipeline programs9From trials and the company's site

Disclosed deals0None found yet

Cash runwayNot availableNo recent cash burn filed

Pipeline9

AtebimetinibPhase 3 · Pancreatic CancerClinicalTrials.gov · fetched Nov 12, 2026
GnPPhase 3 · Pancreatic CancerClinicalTrials.gov · fetched Nov 12, 2026
mGnPPhase 3 · Pancreatic CancerClinicalTrials.gov · fetched Nov 12, 2026
IMM-1-104 + dabrafenib (Treatment Group D)Phase 2 · Advanced Solid TumorClinicalTrials.gov · fetched Nov 12, 2026
IMM-1-104 + modified FOLFIRINOX (Treatment Group C)Phase 2 · Advanced Solid TumorClinicalTrials.gov · fetched Nov 12, 2026
IMM-1-104 + modified Gemcitabine/nab-Paclitaxel (Treatment Group B)Phase 2 · Advanced Solid TumorClinicalTrials.gov · fetched Nov 12, 2026
IMM-1-104 + pembrolizumab (Treatment Group E)Phase 2 · Advanced Solid TumorClinicalTrials.gov · fetched Nov 12, 2026
IMM-1-104 Monotherapy (Treatment Group A)Phase 2 · Advanced Solid TumorClinicalTrials.gov · fetched Nov 12, 2026
IMM-6-415Phase 2 · Advanced Solid Tumor (Phase 1)ClinicalTrials.gov · fetched Nov 12, 2026

Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic AdenocarcinomaPHASE3 · RECRUITING · started Jun 5, 2026ClinicalTrials.gov NCT07562152 · fetched Nov 12, 2026
A Study of IMM-6-415 in RAS/RAF Mutant Solid TumorsPHASE1_PHASE2 · COMPLETED · started Feb 27, 2024ClinicalTrials.gov NCT06208124 · fetched Nov 12, 2026
A Phase 1/2a Study of IMM-1-104 in Participants With Advanced or Metastatic Solid TumorsPHASE1_PHASE2 · ACTIVE_NOT_RECRUITING · started Oct 31, 2022ClinicalTrials.gov NCT05585320 · fetched Nov 12, 2026